InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company specializing in cancer and autoimmune disease treatments, has received approval to conduct a clinical trial for its BCL2 inhibitor, ICP-248, in combination with azacitidine for acute myeloid leukemia (AML) in China.
AML is a type of blood cancer that starts in hematopoietic stem cells and accounts for 80% of adult acute leukemia cases. It is more common in older adults, but also represents 15-20% of pediatric leukemia cases.
ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor that works by restoring programmed cell death, targeting abnormal BCL2 protein expression linked to blood cancers.
Dr. Jasmine Cui, InnoCare’s co-founder and CEO, emphasized the company’s commitment to advancing treatments for blood cancers, aiming to deliver new therapies that benefit patients worldwide.
About InnoCare:
InnoCare is a commercial-stage biopharma company focused on discovering and developing innovative treatments for cancer and autoimmune diseases in China and globally. The company has offices in multiple cities, including Beijing, Shanghai, and the U.S.
